A valid formulation of the analysis of noninferiority trials under random effects meta-analysis

Biostatistics

Volumn 13, Issue 4, 2012, Pages 637-649

  Brittain, Erica H ^a   Fay, Michael P ^a   Follmann, Dean A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Active control trial; Clinical trial; Meta analysis; Noninferiority trial; Random effects; Synthesis method

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID;

ARTICLE; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; COMPUTER SIMULATION; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL;

EID: 84866347190     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxs006     Document Type: Article

References (15)

1. D'AGOSTINO, R. B., MASSARO, J. M. AND SULLIVAN, L. (2003). Non-inferiority trials: design concepts and issues\the encounters of academic consultants in statistics. Statistics in Medicine 22, 169-186. (Pubitemid 36163579)
2. FLEMING, T. R. (2008). Current issues in non-inferiority trials. Statistics in Medicine 27, 317-332. (Pubitemid 351227869)
3. FOOD AND DRUG ADMINISTRATION (FDA) (2010). Guidance for Industry: Non-Inferiority Clinical Trials (March 2010 Draft Guidance). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/.
4. HARTUNG, J. (1999). An alternative method for meta-analysis. Biometrical Journal 41, 901-916.
5. HASSELBLAD, V. AND KONG, D. F. (2001). Statistical methods for comparison to placebo in active-control trials. Drug Information Journal 35, 435-449. (Pubitemid 32524896)
6. HUNG, H. M. J., WANG, S. J., TSONG, Y., LAWRENCE, J. AND O'NEILL, R. T. (2003). Some fundamental issues with non-inferiority testing in active control trials. Statistics in Medicine 22, 213-225. (Pubitemid 36163582)
7. MCCULLOCH, C. E. AND NEUHAUS, J. M. (2011). Prediction of random effects in linear and generalized linear models under model misspecification. Biometrics 67, 270-279.
8. PAULE, R. C. AND MANDEL, J. (1982). Consensus values and weighting factors. Journal of Research of the National Bureau of Standards 87, 377-385.
9. PIEDBOIS, P. AND BUYSE, M. (2004). Meta-analyses based on abstracted data: a step in the right direction, but only a first step. Journal of Clinical Oncology 22, 3839-3841. (Pubitemid 41079861)
10. READ, C. B. (2006). Median unbiased estimators. Encyclopedia of Statistical Sciences 7, 4713-4715.
11. ROTHMANN, M., LI, N., CHEN, G., CHI, G. Y. H., TEMPLE, R. T. AND TSOU, H. H. (2003). Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 22, 239-264. (Pubitemid 36163584)
12. ROTHMANN, M., WIENS, B. L. AND CHAN, I. S. F. (2012). Design and Analysis of Non-inferiority Trials. Boca Raton, FL: Chapman and Hall.
13. SNAPINN, S. M. (2004). Alternatives for discounting in the analysis of noninferiority trials. Journal of Biopharma-ceutical Statistics 14, 263-273. (Pubitemid 38715780)
14. SNAPINN, S. M. AND JIANG, Q. I. (2008). Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Statistics in Medicine 27, 382-391.
15. SUTTON, A. J. AND HIGGINS, J. P. T. (2008). Recent developments in meta-analysis. Statistics in Medicine 27, 625-650. (Pubitemid 351278810)